News Briefing channel feed

Two biotechs go for pub­lic of­fer­ings; Pfiz­er part­ner ex­pands on­col­o­gy col­lab

3 years ago

Io­n­is, As­traZeneca go­ing to FDA with PhI­II da­ta in hand; Glaukos touts dou­ble PhI­II win in eye im­plant

3 years ago

FDA's out­side ex­perts to re­view GSK, As­traZeneca drugs; Biotech gives very ear­ly pos­i­tive in­di­ca­tions for cell ther­a­py

3 years ago

Shang­hai-based cell ther­a­py biotech nabs new funds; Col­orado biotech nets an ac­qui­si­tion

3 years ago
Financing
China

Foghorn co-founder re­signs from board; Guardant and Mer­ck KGaA team up again

3 years ago

Sau­di an­ti-ag­ing group links up with AFAR to dole out re­search grants; US cannabis biotech se­cures UK part­ner

3 years ago

Food al­ler­gy biotech gets $50M loan; Sean Ianchulev’s med­ical de­vice com­pa­ny rais­es a $23M Se­ries B

3 years ago

Small neu­rol­o­gy biotech an­nounces prices its $8M IPO; Vivos put on no­tice af­ter miss­ing fil­ing dead­line

3 years ago

Bei­jing CRO ex­pands agree­ment with Mer­ck KGaA; Ear­ly-stage ven­ture firm clos­es its first fund

3 years ago

Wom­en's health biotech nabs new an­timi­cro­bial treat­ment; Ovid finds part­ner for neu­ro­science col­lab­o­ra­tion

3 years ago

No Q2 call yet for a Col­orado medtech; San Diego biotech col­labs with MD An­der­son

3 years ago

Nor­we­gian biotech to en­act lay­offs; Uni­ty halves its pub­lic of­fer­ing

3 years ago

Astel­las' hot flash­es drug will get speedy re­view at FDA; US opts out of Val­ne­va vac­cine

3 years ago

TYK2 heats up with Ven­tyx eye­ing mid-stage tri­als; Nex­Im­mune cites com­pe­ti­tion in pipeline cull

3 years ago

An an­tibi­otics play­er ax­es staff in wake of PhI­II fail; Hori­zon to fund an­ti­body de­vel­op­ment, with op­tion to buy

3 years ago

Check­point ends tri­al due to Russ­ian in­va­sion; Terns lines up more cash for NASH

3 years ago

Graphite Bio be­gins SCD cell ther­a­py tri­al; Syn­thet­ic Bi­o­log­ic­s' fu­ture rests on VCN ac­qui­si­tion

3 years ago

Pen­ny stock biotech miss­es on its sole clin­i­cal tri­al; Cal­adrius teams up with Roche for pan­cre­at­ic can­cer col­lab­o­ra­tion

3 years ago

BioCryst re­sumes en­roll­ment for im­mune dis­eases drug; Ea­gle buys stake in res­pi­ra­to­ry dis­ease biotech

3 years ago

Clo­vis says it needs mon­ey af­ter re­verse split vot­ed down; Cin­Cor touts PhII da­ta for hy­per­ten­sion drug

3 years ago

Gen­mab and BioN­Tech to col­lab­o­rate on new can­cer can­di­date; Small Aus­tralian biotech sees hope in brain metas­tases tri­al

3 years ago

FDA de­lays PDU­FA date for Lib­tayo lung can­cer com­bo; Swedish biotech hit flunks PhI­II for chemo-en­hanc­ing drug

3 years ago

Af­ter a bust with knee pain drug and 3 Covid-19 flops, Am­pio lays off staff; An­ti­body start­up nabs sec­ond deal in two weeks

3 years ago
R&D

FDA green­lights Mar­ius' oral hy­pog­o­nadism pill; VBL Ther­a­peu­tics makes cuts to its work­force

3 years ago
First page Previous page 20212223242526 Next page Last page
A service from the Financial Times